This is not the most recent version of the article. View current version (14 NOV 2012)

Intervention Protocol

Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)

  1. Nicole Bergner1,
  2. Sabine Kluge1,
  3. Ina Monsef1,
  4. Gerald Illerhaus2,
  5. Andreas Engert1,
  6. Nicole Skoetz1,*

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 5 OCT 2011

DOI: 10.1002/14651858.CD009355


How to Cite

Bergner N, Kluge S, Monsef I, Illerhaus G, Engert A, Skoetz N. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL) (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD009355. DOI: 10.1002/14651858.CD009355.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    University Hospital of Freiburg, Department I of Internal Medicine, Freiburg, Germany

*Nicole Skoetz, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. nicole.skoetz@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 5 OCT 2011

SEARCH

This is not the most recent version of the article. View current version (14 NOV 2012)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main objective of this Cochrane review is to evaluate the role of additional chemotherapy to HD-MTX in the treatment of immunocompetent PCNSL patients with respect to overall survival (OS), progression-free survival (PFS), response rate, adverse events (AE), treatment-related mortality (TRM) and quality of life (QoL).